Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG Face-to-face event at the Zwingenberg site Executive Board and Supervisory Board approved by a clear majority Silent partnership with the State of Hesse approved by a very large majority Zwingenberg, Germany, 12 March 2024 – At today´s Annual General Me [ … ]

Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials First patent application registered BRAIN Biotech relies on protein engineering expertise and bioinformatics for rational protein design Zwingenberg / Neuried (Germany), March 5, 2024 - BRAIN Biotech AG, leading  [ … ]

BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives Zwingenberg, Germany, 29 February 2024 – At its meeting today and with the approval of the Supervisory Board, the Management Board of BRAIN Biotech AG has resolved, to issue convertible bonds in the total nominal amount of EUR 5.0  [ … ]

3M FY 23/24:  BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24 Strong BioScience business in Q1 BioProducts growth to accelerate over the next quarters Optimistic outlook for the business year targeting revenue range of € 58 million to € 62 million Zwingenberg, Germany, 28. February 2024 – BRAIN Biotech AG, a lea [ … ]

Annual Report 2022/23: BRAIN Biotech AG successfully executes growth strategy   Group sales grew by 11.8 %, 9.8 % all organic All divisions contribute to growth Successful execution of One-BioProducts strategy Strong progress on BioIncubator pharmaceutical project Deucrictibant Zwingenberg, Germany, 17. January 2024 – BRAIN Biotech AG, a leadi [ … ]